Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach
This study has been completed.
Study NCT00061932 Information provided by National Cancer Institute (NCI)
First Received on June 5, 2003. Last Updated on December 21, 2012
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Mixed Adenocarcinoma of the Stomach
Recurrent Gastric Cancer
Stage IIIB Gastric Cancer
Stage IIIC Gastric Cancer
Stage IV Gastric Cancer
Additional conditions recognized in this trial
Adenocarcinoma
Adenocarcinoma, Mucinous
Stomach Neoplasms
More general conditions related to this trial
Carcinoma
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Cystic, Mucinous, and Serous
Neoplasms, Glandular and Epithelial
Stomach Diseases
Interventions listed in this trial
bortezomib
irinotecan hydrochloride
laboratory biomarker analysis
Additional drug interventions recognized in this trial
Camptothecin
Irinotecan
More general drug interventions related to this trial
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protease Inhibitors
Radiation-Sensitizing Agents
Therapeutic Uses
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Sponsors listed in this trial
National Cancer Institute (NCI)
Back to top of Main Content
